This article is more than 5 years old. Information may no longer be current.
Rescula gets FDA approval as concomitant glaucoma therapy
Click Here to Manage Email Alerts
WASHINGTON — Rescula (unoprostone isopropyl ophthalmic solution 0.15%; CIBA Vision) has received U.S. Food and Drug Administration (FDA) approval for the lowering of intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension who are intolerant of other IOP lowering medications or insufficiently responsive to another IOP lowering medication.
“In terms of Rescula’s IOP lowering effect, we’ve seen a 13% to 17.4% from baseline lowering of IOP,” George Minno, PhD, director of medical marketing for CIBA Vision U.S. Ophthalmics, said. Clinical studies showed that in patients with mean baseline IOP of 23 mm Hg, Rescula lowers IOP by approximately 3 to 4 mm Hg throughout the day.
“And it has an excellent safety profile,” Dr. Minno added. “We haven’t seen any peak and trough effects that are associated with other glaucoma agents. There is no loss of efficacy over time and Rescula’s maximum effect is established as soon as 24 hours after instillation.”
Additionally, cardiovascular and pulmonary systems were not affected by Rescula use. No allergic reactions have been reported. The most common side effects of Rescula were stinging and burning upon instillation.
A low incidence of gradual iris color change has been reported with Rescula use. However, the 0.12% incidence of iris pigment change associated with Rescula is 100-fold less than that seen with Xalatan (latanoprost, Pharmacia), according to Dr. Minno. Only one out of 813 patients experienced a change in eye color during the Rescula clinical trials.
Chemistry and function
Unoprostone was developed from a prostaglandin metabolite. The drug molecule is a docosanoid — essentially different in molecular structure from all other glaucoma compounds, according to Dr. Minno. Docosanoid compounds are based on a chain of 22 carbon atoms, as opposed to the 20 carbon atoms of primary prostaglandin known as eicosanoids.
“Although Rescula looks like a prostaglandin, it doesn’t behave like one,” Dr. Minno said. “It doesn’t bind to any of the same receptors and it really doesn’t have a lot of the properties that you would expect if you were comparing it with something like latanoprost.”
The approved dosage for Rescula is one drop in the affected eye twice daily. It may be used concomitantly with other topical ophthalmic drugs to lower IOP. If two drugs are used, it is recommended that they be administered at least 5 minutes apart.
“When instilled in the eye, Rescula is believed to reduce elevated IOP by increasing the outflow of aqueous humor,” Dr. Minno said, but the exact mechanism is unknown at this time. After application to the eye, unoprostone isopropyl is absorbed through the cornea and conjunctival epithelium where it is hydrolyzed by esterases to unoprostone-free acid. Rescula appears to lower IOP without affecting cardiovascular or pulmonary function, Dr. Minno said. Stinging and burning were the most common reported side effects reported with Rescula use.
In clinical studies of Rescula, only one patient experienced a change in iris color. According to Thomas K. Mundorf, MD, that one incidence of iris color change in a patient receiving 0.15% unoprostone isopropyl was so gradual that it was not detected by the patient or the doctor, but by clinical investigators. “This one case was found, and it wasn’t found by the doctor or the patient, in out of about 850 patients,” Dr. Mundorf said. “So it looks like it is a very uncommon effect.”
For Your Information:
- George Minno, PhD, can be reached at CIBA Vision Corp., 11460 Johns Creek Parkway, Duluth, GA 30097-1556; (678) 415-3875; fax: (678) 415-7474; e-mail: georgeminno@cibavision.novartis.com.
- Thomas K. Mundorf, MD, can be reached at 1718 E. 4th St.,Ste. 806, Charlotte, NC 28204; (704) 334-3222; fax: (704) 334-1532.
- Rescula is manufactured by CIBA Vision, 11460 Johns Creek Parkway, Duluth, GA 30097.